SLC5A2 and hydrops fetalis: As evidence of the efficacy of SGLT-2 inhibitors continued to grow, many trails and meta-analysis on these drugs have expanded their prescriptions from diabetes patients only to also include patients with HF without type 2 DM (28–32).